PP74 Taking A Lifecycle Approach To Scottish Medicines Consortium Budget Impact Analysis

Introduction The Scottish Medicines Consortium (SMC) conducts early health technology assessment of new medicines in Scotland. While budget impact is not a factor decisions on reimbursement, information provided initially through horizon scanning reports for high (estimated net >GBP 500,000 [EUR 585,710] per annum) to aid financial planning and implementation advice at the local level, later templates from submitting company issued alongside SMC advice. This research aimed understand how used evaluate benefits lifecycle approach analysis. Methods Health Board users were surveyed explore degree utilization identify areas improvement, including need cross-validate estimates with those company. Responses analyzed quantitatively qualitatively, comments coded Nvivo (QSR International) themes established thematic Results initial responses received (n=17) representation 57 percent Boards (i.e., payers) covering 79 population. Preliminary results showed that while valued, 69 respondents found them ‘somewhat useful’, suggesting scope improvement. Almost half (48%) medicines, only 30 using all medicines. majority (76%) thought there would be value linking throughout process. An emerging theme was some complex inflexible, simpler, more adaptable tool process welcomed. Priorities identified improving template included adapting population adjusting medicine prices reflect confidential discounts. Conclusions suggests valued by strong support engaging stakeholders medicine’s lifecycle. Simplifying templates, increasing their adaptability, providing guidance training use will key steps this important part